메뉴 건너뛰기
Ugeskrift for Laeger
Volumn 166, Issue 11, 2004, Pages 1028-1029
Treatment of septic shock with nitric oxide synthase inhibitor: The baby and the bathwater;Nitrogenoxidsyntasehæmmer-behandling ved septisk shock: Barnet og badevandet
Author keywords

[No Author keywords available]
Indexed keywords

N(G) METHYLARGININE; NITRIC OXIDE SYNTHASE INHIBITOR; NITRIC OXIDE SYNTHASE; VASOCONSTRICTOR AGENT;
EID: 1542572920     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note
Times cited : (3)
References (5)
  • 1
    • 0037309925 scopus 로고    scopus 로고
    • Science, medicine, and the future: Pathogenesis of sepsis: New concepts and implications for future treatment
    • Bochud P-Y, Calandra T. Science, medicine, and the future: pathogenesis of sepsis: new concepts and implications for future treatment. BMJ 2003;326:262-6.
    • (2003) BMJ , vol.326 , pp. 262-266
    • Bochud, P.-Y.1    Calandra, T.2
  • 2
    • 9144268892 scopus 로고    scopus 로고
    • G-methyl-L-arginine hydrochloride (546C88) in patients with septic shock: Results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002)
    • G-methyl-L-arginine hydrochloride (546C88) in patients with septic shock: Results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002). Crit Care Med 2004;32:13-20.
    • (2004) Crit Care Med , vol.32 , pp. 13-20
    • Watson, D.1    Grover, R.2    Anzueto, A.3
  • 3
    • 9144220131 scopus 로고    scopus 로고
    • G-methyl-L-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: Results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002)
    • G-methyl-L-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: Results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002). Crit Care Med 2004;32:1-12.
    • (2004) Crit Care Med , vol.32 , pp. 1-12
    • Bakker, J.1    Grover, R.2    McLuckie, A.3
  • 4
    • 4444273012 scopus 로고    scopus 로고
    • Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock
    • Lopez A, Lorente JA, Steingrub J et al. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock. Crit Care Med 2004;32:21-30.
    • (2004) Crit Care Med , vol.32 , pp. 21-30
    • Lopez, A.1    Lorente, J.A.2    Steingrub, J.3
  • 5
    • 0035829842 scopus 로고    scopus 로고
    • Early goal-directed therapy in the treatment of severe sepsis and septic shock
    • Rivers E, Nguyen B, Havstad S et al, and Early Goal-Directed Therapy Collaborative Group. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345:1368-77.
    • (2001) N Engl J Med , vol.345 , pp. 1368-1377
    • Rivers, E.1    Nguyen, B.2    Havstad, S.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.